Reuben C, Phondke G P
Immunology. 1979 Nov;38(3):547-51.
The development of a heterologous anti-lymphocyte serum (ALS) capable of specifically suppressing the delayed hypersensitivity (DH) response is reported. This ALS, termed ALS(CMI), was prepared against lymph node cells from rats which had been immunized against sheep erythrocytes (SRBC) following treatment with cyclophosphamide which is known to enhance the DH response and suppress the humoral immune response. The effect of ALS(CMI) on the primary DH response to SRBC using the footpad swelling test was studied. Its effect on the primary humoral immune response to SRBC was also studied using the Jerne plaque assay technique. ALS(CMI) suppressed the humoral antibody response to SRBC and the DH response to a third party antigen only when administered before the antigen, having no effect when administered post-antigenically. On the other hand, ALS(CMI) significantly suppressed the primary DH response to SRBC when administered either before or after the antigen.
报道了一种能够特异性抑制迟发型超敏反应(DH)的异种抗淋巴细胞血清(ALS)的研制情况。这种被称为ALS(CMI)的抗淋巴细胞血清是用环磷酰胺处理后再免疫羊红细胞(SRBC)的大鼠淋巴结细胞制备而成的,已知环磷酰胺可增强DH反应并抑制体液免疫反应。采用足垫肿胀试验研究了ALS(CMI)对针对SRBC的初次DH反应的影响。还用耶尔恩斑试验技术研究了其对针对SRBC的初次体液免疫反应的影响。ALS(CMI)仅在抗原之前给药时才会抑制对SRBC的体液抗体反应以及对第三方抗原的DH反应,抗原后给药则无作用。另一方面,ALS(CMI)在抗原之前或之后给药时均能显著抑制对SRBC的初次DH反应。